Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Methotrexate × Sarcoma × Clear all

Status

Sponsor Class

OTHER 36 NIH 10 NETWORK 10 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 15 Other hematologic neoplasm 12 Head & Neck 6 Breast 4 Myeloid 3 Sarcoma 1 Plasma cell 1 Genitourinary 1 Dermatologic 1 Classical hematology 1 CNS 1

Conditions

Interventions

Doxorubicin 40 Imatinib Mesylate 30 Cyclophosphamide 20 Sunitinib 19 pembrolizumab 17 Gemcitabine 17 Temozolomide 16 Irinotecan 13 Bevacizumab 12 pazopanib 11 nilotinib 11 Trabectedin 11 ripretinib 10 fludarabine 9 Docetaxel 9 Carboplatin 9 olaratumab 8 eribulin 8 Ibandronic Acid 8 avapritinib 7 anlotinib 7 Radiation 7 Paclitaxel 7 Ifosfamide 7 spartalizumab 6 regorafenib 6 Vincristine 6 Fluorouracil 6 Dacarbazine 6 Cisplatin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02383901 2016-09-05

FORTO

Isofol Medical AB

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡